Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/TGTX
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

TG Therapeutics Inc (TGTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

TG Therapeutics (TGTX) trades at $54.46, up 0.91% on the day, amid a bearish technical signal despite strong analyst buy ratings. The company reported robust revenue growth with 2025 revenue of $616.29 million and net income of $447.18 million, though recent quarterly EPS misses and a shareholder investigation announcement on September 28, 2026, create near-term uncertainty. Key support sits at $52, with resistance at $54.
Outlook remains mixed; Wall Street consensus is bullish with an $80.50 price target, but risks include ongoing legal scrutiny, competitive pressures in MS treatments, and cash flow volatility. The stock's high valuation multiples and earnings misses warrant caution despite positive institutional accumulation and product growth catalysts.
Read full analysis

Key Stats

  • Market Cap
    $8.17B
  • Volume
    1,550,078
  • Sector
    Health
  • 52W High
    $59.06
  • 52W Low
    $26.94
  • Typical Hold Time
    16 Days
  • Enterprise Value
    $8.37B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$54.53
52W Low: $26.94
12 Mar 2026
52W High: $59.06
09 Jul 2026

Track TG Therapeutics Inc (TGTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.94 and a high of $59.06, highlighting its annual price range. Buy and sell TG Therapeutics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Most Recent News

Content is generated by Aura AI

Investigation launched into Enova over withdrawn bank acquisition and stock drop

Pomerantz LLP is investigating Enova International for potential securities fraud after the company withdrew its application to acquire Grasshopper Bancorp, which would have made it a bank holding company. Enova cited unclear regulatory standards and...

Market News
4 hours ago
GlobeNewsWire
Bearish
news icon
Investigation launched into Enova over withdrawn bank acquisition and stock drop

Major BDCs trade at steep discounts, signaling market fears of extreme loan losses despite strong credit performance.

Five major Business Development Companies (BDCs) are trading at significant discounts to their net asset value (NAV), suggesting the market expects severe loan losses that are not supported by current credit data. These BDCs hold senior secured, dive...

Market News
4 hours ago
Seeking Alpha
Neutral
Major BDCs trade at steep discounts, signaling market fears of extreme loan losses despite strong credit performance.

New York housing inventory rises nearly 10% in September as prices continue to climb.

In September 2026, New York State's housing inventory increased by 9.8% year-over-year, reaching 35,294 homes available for sale. Despite this rise in supply, home prices continued to grow, with the median sales price up 5.9% to $450,000 compared to ...

Market News
4 hours ago
New York State Association Of Realtors®
Neutral
New York housing inventory rises nearly 10% in September as prices continue to climb.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $8.17B
  • Volume
    1,550,078
  • Sector
    Health
  • 52W High
    $59.06
  • 52W Low
    $26.94
  • Typical Hold Time
    16 Days
  • Enterprise Value
    $8.37B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$54.53
52W Low: $26.94
12 Mar 2026
52W High: $59.06
09 Jul 2026

Track TG Therapeutics Inc (TGTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, TG Therapeutics Inc has traded between a low of $26.94 and a high of $59.06, highlighting its annual price range. Buy and sell TG Therapeutics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!